OncoInv signs distribution agreement for OncoSeek® in El Salvador

November 27, 2025

OncoInv has signed a new distribution partnership with MaxBloch Clinical Laboratories in El Salvador, expanding the reach of its OncoSeek® multi-cancer detection blood test to Central America.

The agreement marks another step in OncoInv’s international growth strategy and its commitment to making early cancer detection affordable and available to all. The collaboration will enable healthcare providers in El Salvador to access OncoSeek®, a CE-marked diagnostic test designed to detect nine of the world’s most lethal cancers from a single blood sample.

“This partnership is part of our ongoing mission to bridge global health inequalities,” said Jesper Verhey, CCO, OncoInv. “The cancer burden is growing, but so is our ability to act. Multi-cancer detection is not about if, but when and how we come together to make it a reality for all. By joining forces with MaxBloch SA de CV, we bring OncoSeek® closer to the people who need it most.”

OncoSeek® combines widely accessible laboratory technology with advanced machine learning analysis, offering a low-cost and scalable solution suitable for both high-income and resource-limited settings. The product is offered not-for-profit in the public sector in low- and middle-income countries.

About MaxBloch Clinical Laboratories

MaxBloch Clinical Laboratories is one of El Salvador’s most established providers of clinical diagnostic services, with a history spanning more than 80 years. Founded by Dr. Max Bloch, an internationally recognised physician and researcher, the organisation has grown into a nationwide network of laboratory centres offering a wide range of routine and specialised tests. MaxBloch is known for its scientific rigor, patient-centred approach and strong commitment to ethical practice, refraining from financial incentives to referring physicians. The organisation operates under internationally aligned quality standards, including ISO 15189:2022, ensuring reliable and accessible diagnostics for communities throughout El Salvador.

For more information about MaxBloch Clinical Laboratories, visit www.maxbloch.com

Click here for more information about OncoSeek®

More news

Oncology experts discuss the future of multi-cancer detection in Madrid

February 5th, 2026

On February 9, OncoInv will host an exclusive expert meeting at Madrid Health Hub, bringing together leading voices in oncology to discuss the evolving role of multi-cancer early detection (MCD) in clinical practice...

Read more
Jesper Verhey appointed CEO to lead OncoInv's next phase of accelerating impact in early cancer detection

February 3rd, 2026

As of 1 February, Jesper Verhey MSc, has taken on the role of CEO of OncoInv. This step marks the next phase in the company’s development, building on the progress of recent years and placing responsible implementation and real-world evidence generation at the centre of its work...

Read more
The University of Costa Rica launches its multi-cancer detection program using the OncoSeek® test

January 15th, 2026

OncoInv collaborates with the Universidad de Costa Rica (UCR) to support the introduction of the OncoSeek® multi-cancer detection test in Costa Rica. Through this collaboration, the test is now available within a public academic and clinical setting, marking an important step in expanding access to advanced cancer detection technologies in the region...

Read more